Array BioPharma Inc. (ARRY) Broker Price Targets For The Coming Week
- Author: Zachary Reyes Jun 01, 2017,
Jun 01, 2017, 14:12
NLST's SI was 2.83 million shares in May as released by FINRA.
Media headlines about Array Biopharma (NASDAQ:ARRY) have trended somewhat positive recently, Alpha One Sentiment reports. Highbridge Capital Management LLC now owns 144,790 shares of the biopharmaceutical company's stock valued at $977,000 after buying an additional 109,852 shares in the last quarter. It was reported on May, 30 by Barchart.com. (ARRY) were valued at $7.58 and moved -3.56% as of a recent closing trade. Float is the number of shares available for trading of a particular stock. It has outperformed by 159.81% the S&P500.
Among 18 analysts covering Dish Network Corp.
Sell-side analysts also have something to say about this company. Year to date is -42.34%, -29.01% over the last quarter, -47.63% for the past six months and -74.38% over the last 12 months. The mean target of $13.00 should be compared with the price when the stock was languishing around $3.10 a share. Barclays Capital upgraded the stock to "Equal-Weight" rating in Tuesday, February 16 report. They now have a United States dollars 8 price target on the stock. This rating uses a scale from 1 to 5.
Shares of the company have shown an EPS growth of 8.60% in the last 5 years. Germany-based Dekabank Deutsche Girozentrale has invested 0.01% in Array Biopharma Inc (NASDAQ:ARRY). Its down 0.19, from 0.95 in 2016Q3. 51 funds opened positions while 97 raised stakes. Cubist Systematic Strategies Ltd Liability Company holds 0% or 4,400 shares. First Mercantile Tru holds 9,725 shares or 0.01% of its portfolio. Deutsche Fincl Bank Ag holds 0% or 66,825 shares. Guggenheim Capital Llc reported 14,095 shares. Envestnet Asset Management has 770 shares for 0% of their portfolio. Sei Investments has 127,251 shares. Spot Trading Limited Liability Co has invested 0% in CorMedix Inc. Pinnacle Assocs invested in 3.21 million shares or 0.57% of the stock. Vanguard Grp has invested 0% in Sientra Inc (NASDAQ:SIEN).
Since December 9, 2016, it had 4 buys, and 1 sale for $7,351 activity. The insider Ortolf Tom A sold $302,750. $3,237 worth of CorMedix Inc. $5,382 worth of DISH Network Corp (NASDAQ:DISH) was sold by ORBAN PAUL W. 15,000 shares were sold by Lynch Roger, worth $945,750 on Monday, May 1.
Support is likely to come between $7.57 a share to $7.29 a share level. The institutional ownership stake in the corporation is 62.60%. Equity Comwlth (NYSE:EQC) was raised too.
Investors sentiment decreased to 1.3 in Q4 2016. Its up 0.29, from 0.83 in 2016Q3.
01/30/2017 - Array BioPharma Inc. was downgraded to "market perform" by analysts at Leerink Swann. In that case, its shares would mark a 7.25% decline from the most recent price. Point72 Asset Mgmt L P accumulated 1.57 million shares. Royal Bank & Trust Of Canada reported 44,579 shares or 0% of all its holdings.
Bnp Paribas Arbitrage invested 0% of its portfolio in Array Biopharma Inc (NASDAQ:ARRY). Citigroup reported 624,314 shares. Employees Retirement Association Of Colorado invested 0% of its portfolio in Array Biopharma Inc (NASDAQ:ARRY). 4,357 were accumulated by Argent Tru.
Array BioPharma Inc. (ARRY) failed to surprise the stock market in its last reported earnings when it earned -$0.21 a piece versus the consensus-estimated -$0.16. Aqr Management Lc reported 131,012 shares stake. 1St Advsrs holds 0.01% or 10,143 shares. We see here that Array BioPharma Inc. Cornerstone Advisors has invested 0% in Array Biopharma Inc (NASDAQ:ARRY).
Out of the brokerage recommendations 8 rate Array Biopharma Inc (NASDAQ:ARRY) stock a Strong Buy, 0 rate the stock a Buy, 1 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Therefore 50% are positive. Array Biopharma has a one year low of $3.10 and a one year high of $13.40. The rating was maintained by Stifel Nicolaus with "Buy" on Friday, August 5. The firm earned "Buy" rating on Friday, June 3 by SunTrust. Stifel Nicolaus maintained the shares of ARRY in report on Friday, August 5 with "Buy" rating. The firm has "Overweight" rating given on Monday, September 26 by Piper Jaffray. Oppenheimer maintained Citigroup Inc (NYSE:C) on Friday, January 29 with "Outperform" rating. The stock has "Neutral" rating by JP Morgan on Friday, February 3. The company was maintained on Monday, September 26 by Leerink Swann.
06/02/2016 - SunTrust began new coverage on Array BioPharma Inc. giving the company a "buy" rating. The company's market cap is $1.39 billion. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib. The company's current price-earnings ratio amounts above the average P/E ratio of 142.43 times earnings.